Skip to main content
SpringerLink
Log in

Hydroxyethylstarch as a Risk Factor for Acute Renal Failure

Is a Change of Clinical Practice Indicated?

  • Current Opinion
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Hypovolaemia is extremely common among surgical and intensive care patients. The best strategy for volume replacement therapy has been the focus of debate for several years. The lack of acceptance of hydroxyethylstarch (HES) for volume replacement therapy is most likely due to reports of abnormal coagulation and to recently published studies indicating negative effects of HES on renal function. All HES solutions are not created equal — they widely differ with regard to their physicochemical characteristics (concentration, mean molecular weight (Mw), degree of substitution [DS], C2/C6-substitution ratio). These differences have important consequences for adverse effects such as alterations in the coagulation process and on kidney function. Conflicting results about the effects of different HES solutions on renal function may also be due to varying clinical protocols, selection of patients, and different criteria for volume replacement. Theoretical and documented hazards are associated with each kind of volume replacement therapy. There appears to be no reason to banish modern HES preparations with a low or medium Mw (e.g. 70, 130 or 200kD) and a low DS (0.4 or 0.5) in patients without pre-existing kidney dysfunction. In patients with known renal dysfunction (e.g. plasma creatinine level >3 mg/dl), all HES preparations should be used cautiously and other volume replacement regimens (e.g. gelatins) should be considered since no convincing data are yet available for the latest generation of HES (Mw 130; DS 0.4).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Fig. 2
Table II
Fig. 3
Table III
Table IV

Similar content being viewed by others

References

  1. Deane SA, Gaudry PL, Woods P, et al. The management of injuries - a review of death in hospital. Aust N Z J Surg 1988; 58: 463–9

    Article  PubMed  CAS  Google Scholar 

  2. Edwards JD. A new debate: colloid versus colloid?. In: Vincent JL, editor. Yearbook of Intensive Care and Emergency Medicine. Berlin, Heidelberg, New York: Springer, 1994: 152–64

    Google Scholar 

  3. Cittanova ML, Leblanc I, Legendre Ch, et al. Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet 1996; 348: 1620–2

    Article  PubMed  CAS  Google Scholar 

  4. De Labarthe A, Jacobs F, Blot F, et al. Acute renal failure secondary to hydroxyethylstarch administration in a surgical patient. Am J Med 2001; 111: 417–8

    Article  PubMed  Google Scholar 

  5. Schortgen F, Lacherade JC, Bruneel F, et al. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicenter randomised study. Lancet 2001; 357: 911–6

    Article  PubMed  CAS  Google Scholar 

  6. Peron S, Mouthon L, Guettier C, et al. Hydroxyethyl starch-induced renal insufficiency after plasma exchange in a patient with polymyositis and liver cirrhosis. Clin Nephrol 2001; 55: 408–11

    PubMed  CAS  Google Scholar 

  7. Byrick RJ, Rose DK. Review article: pathophysiology and prevention of acute renal failure: the role of the anaesthetist. Can J Anaesth 1990; 37: 457–67

    Article  PubMed  CAS  Google Scholar 

  8. Rahn KH. Acute disturbances of renal function. Chest 1991; 100: 197S–9S

    PubMed  CAS  Google Scholar 

  9. Moran M, Kapsner C. Acute renal failure associated with elevated plasma oncotic pressure. N Engl J Med 1987; 317: 150–3

    Article  PubMed  CAS  Google Scholar 

  10. Kulka PJ, Tryba M, Zenz M. Preoperative alpha-2-adrenergic receptor agonists prevent the deterioration of renal function after cardiac surgery: results of a randomized, controlled trial. Crit Care Med 1996; 24: 947–52

    Article  PubMed  CAS  Google Scholar 

  11. Lote CJ, Harper L, Savage COS. Mechanisms of acute renal failure. Br J Anaesth 1996; 77: 82–9

    Article  PubMed  CAS  Google Scholar 

  12. Aronson S, Blumenthal R. Perioperative renal dysfunction and cardiovascular anesthesia: concerns and controversies. J Cardiothorac Vasc Anesth 1998; 12: 567–86

    Article  PubMed  CAS  Google Scholar 

  13. Lindeman RD. Changes in renal function with aging: Implications for treatment. Drugs Aging 1992; 2: 423–31

    Article  PubMed  CAS  Google Scholar 

  14. Ritschel WA. Gerontokinetics: the pharmacokinetics of drugs in the elderly patient. Caldwell (NJ): Telford Press, 1988: 114–24

    Google Scholar 

  15. Beyer R, Harmening U, Rittmeyer O, et al. Use of modified fluid gelatin and hydroxyethyl starch for colloidal volume replacement in major orthopaedic surgery. Br J Anaesth 1997; 78: 44–50

    Article  PubMed  CAS  Google Scholar 

  16. Hussain SF, Drew PJT. Acute renal failure after infusion of gelatins. BMJ 1989; 299: 1137–8

    Article  PubMed  CAS  Google Scholar 

  17. Kurnik BRC, Singer F, Groh WC. Case report: dextran-induced acute renal failure. Am J Med Sci 1991; 302: 28–30

    Article  PubMed  CAS  Google Scholar 

  18. Figueroa JE, Burgos-Calderon R. Renal toxicity of low molecular weight dextran: a review of the literature. J La State Med Soc 1974; 126: 425–7

    PubMed  CAS  Google Scholar 

  19. Feest TG. Low molecular weight dextran: a continuing cause of acute renal failure. BMJ 1976; 2: 1300–1

    Article  PubMed  CAS  Google Scholar 

  20. Treib J, Haass A, Pindur G, et al. HES 200/0.5 is not HES 200/0.5 - influence of the C2/C6 hydroxyethylation ratio of hydroxyethyl starch (HES) on hemorheology, coagulation and elimination kinetics. Thromb Haemost 1995; 74: 1452–6

    PubMed  CAS  Google Scholar 

  21. Traylor RJ, Pearl R. Crystalloid versus colloid: all colloids are not created equal. Anesth Analg 1996; 83: 209–12

    PubMed  CAS  Google Scholar 

  22. Kief H, Engelhart K. Reabsorptive Vacuolisation der gewundenen Nierenhauptstücke (sog. osmotische Nephrose). Frank Zeitschr für Path 1966; 75: 53–9

    CAS  Google Scholar 

  23. Iana A, Schwartz D. Renal tubular cellular and molecular events in acute renal failure. Nephron 1994; 68: 413–8

    Article  Google Scholar 

  24. Chinitz JL, Kim KE, Onesti G, et al. Pathophysiology and prevention of dextran-40-induced anuria. J Lab Clin Med 1971; 77: 76–87

    PubMed  CAS  Google Scholar 

  25. Hester J, McEntegrat C, Hulse JD, et al. Clinical study no. 607-85-09. Rockville (MD); Dupont

  26. Kortilla K, Grohn P, Gordin A, et al. Effects of hydroxyethyl starch and dextran on plasma volume and blood hemostasis and blood coagulation. J Clin Pharmacol 1984; 24: 273–82

    Google Scholar 

  27. Mizuta S, Ikeda K, Iguchi K. Clinical study with hydroxyethly starch 200/0.6: hemodynamic data, metabolism and elimination. Med Consult New Remedies 1971: 8: 2493–2500

    Google Scholar 

  28. Kloetz U, Kroemer U. Clinical pharmacokinetic considerations in the use of plaxma volume expanders. Clin Pharmacokinet 1987; 12: 123–35

    Article  Google Scholar 

  29. Baron JF. Clinical use of hydroxyethyl starches. In: Vincent JL, editor. Update in intensive care and emergency medicine. Vol. 14. New York (NY); Springer, 1991: 403–14

    Article  Google Scholar 

  30. Druml W, Pölzleitner D, Laggner AN, et al. Dextran-40, acute renal failure, and elevated plasma oncotic pressure. N Engl J Med 1988; 318: 252–3

    Google Scholar 

  31. Rozich JD, Paul RV. Acute renal failure precipitated by elevated colloid osmotic pressure. Am J Med 1989; 87: 358–60

    Article  Google Scholar 

  32. Legendre C, Thervet E, Page B, et al. Hydroxyethylstarch and osmotic-nephrosis-like lesions in kidney transplantation. Lancet 1993; 342: 248–9

    Article  PubMed  CAS  Google Scholar 

  33. Coronel B, Mercatello A, Martin X, et al. Hydroxyethylstarch and renal function in kidney transplant recipients. Lancet 1997; 349: 884

    Article  PubMed  CAS  Google Scholar 

  34. London MJ, Ho SJ, Triedman JK, et al. A randomized clinical trial of 10% pentastarch (low molecular weight hydroxyethyl starch) versus 5% albumin for plasma volume expansion after cardiac operations. J Thorac Cardiovasc Surg 1989; 97: 785–97

    PubMed  CAS  Google Scholar 

  35. Vogt NH, Bothner U, Lerch G, et al. Large-dose administration of 6% hydroxyethyl starch 200/0.5 for total hip arthroplasty: plasma homeostasis, hemostasis, and renal function compared to use of 5% human albumin. Anesth Analg 1996; 83: 262–8

    PubMed  CAS  Google Scholar 

  36. Boldt J, Müller M, Mentges D, et al. Volume therapy in the critically ill: is there a difference? Intensive Care Med 1998; 24: 28–36

    Article  PubMed  CAS  Google Scholar 

  37. Kumle B, Boldt J, Piper SN, et al. The influence of different intravascular volume replacement regimens on renal function in the elderly. Anesth Analg 1999; 89: 1124–30

    Article  PubMed  CAS  Google Scholar 

  38. Allison KP, Gosling P, Jones S, et al. Randomized trial of hydroxyethyl starch versus gelatine for trauma resuscitation. J Trauma 1999; 47: 1114–21

    Article  PubMed  CAS  Google Scholar 

  39. Deman A, Peeters P, Sennesael J. Hydroxyethyl starch does not impair immediate renal function in kidney transplant recipients: a retrospective, multicenter analysis. Nephrol Dial Transplant 1999; 14: 1517–20

    Article  PubMed  CAS  Google Scholar 

  40. Boldt J, Lehmann A, Römpert R, et al. Volume therapy with a new hydroxyethyl starch solution in cardiac surgical patients before cardiopulmonary. J Cardiothorac Vasc Anesth 2000; 14: 264–8

    Article  PubMed  CAS  Google Scholar 

  41. Dehne MG, Mühling J, Sablotzki A, et al. Hydroxyethylstarch (HES) does not directly affect renal function in patients with no prior renal impairment. J Clin Anesth 2001; 13: 103–11

    Article  PubMed  CAS  Google Scholar 

  42. Astiz ME, Rackow EC. Crystalloid-colloid controversy revisited. Crit Care Med 1999; 27: 34–5

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. The author has no conflicts of interest that are directly relevant to the content of this manuscript.

Author information

Authors and Affiliations

  1. Department of Anaesthesiology and Intensive Care Medicine, Klinikum der Stadt Ludwigshafen, Bremserstr. 79, D-67063, Ludwigshafen, Germany

    Joachim Boldt

Authors
  1. Joachim Boldt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joachim Boldt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Boldt, J. Hydroxyethylstarch as a Risk Factor for Acute Renal Failure. Drug-Safety 25, 837–846 (2002). https://doi.org/10.2165/00002018-200225120-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200225120-00002

Keywords

Search

Navigation